NCT07330037 2026-01-09TALENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectable NSCLC Without pCR After Neoadjuvant ChemoimmunotherapyTianjin Medical University Cancer Institute and HospitalPhase 2 Recruiting41 enrolled